Sažetak
Objective: Hashimoto's thyroiditis (HT) is an autoimmune disorder affecting the thyroid gland and may present as goiter or atrophic thyroiditis that may result in various metabolic and inflammatory disorders. The aim of this study is to determine the changes in serum levels of interleukin-17 (IL-17), IL-23, neopterin, and nesfatin-1 parameters in HT patients and to evaluate the possible relationship among these parameters.
Material and methods: 90 HT patients and 30 healthy individuals were included in this study. Demographic data of the patients included in the study were recorded and detailed physical examinations were performed. IL-17, IL-23, neopterin, and nesfatin-1 levels were measured in the serum samples of the participants by the ELISA method.
Results: Serum IL-17, IL-23, neopterin, and nesfatin-1 levels were significantly higher in the HT group compared to the control group. Statistically significant differences were observed between all the groups except euthyroid HT versus HT treated with levothyroxine for nesfatin-1 at the 0.05 level.
Conclusion: Our study showed that IL-17 and IL-23, neopterin, and nesfatin-1 levels are involved in the etiopathogenesis of HT especially the contribution of both IL-17 and IL-23 to the inflammation seen in autoimmune diseases such as Hashimoto's. These variables could be used as potential biomarkers in the diagnosis, prognosis, and fellow up of HT disease. Further studies are needed to investigate the exact etiology of HT since its mechanism was not fully elucidated.
Ključne reči
Reference
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.